Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries has submitted a quarterly compliance statement to BSE confirming that it has no unutilized funds remaining as of December 31, 2025 from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP). Since there are no proceeds pending utilization, no detailed Annexure-A disclosure has been furnished. The filing is a routine SEBI regulatory requirement under Regulation 32(1) read with the December 2019 SEBI circular on deviation/variation reporting.
This is a purely procedural compliance filing with no material impact on shareholders or the stock price, as the company is simply confirming that there is nothing outstanding to report regarding issue proceeds.